IOV-2001

IOV-2001 is an autologous, non-genetically modified, polyclonal T-cell therapy developed by Iovance Biotherapeutics for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The therapy consists of adoptive cell transfer using peripheral blood lymphocytes (PBLs) collected from the patient. After a preparative regimen with lymphodepleting chemotherapy (cyclophosphamide and fludarabine), patients receive a single infusion of IOV-2001 followed by up to six doses of interleukin 2 (IL-2). The mechanism involves enhanced cytotoxic T-cell responses against autologous leukemic B-cells, leading to immunologic cytotoxicity and replacement of dysfunctional lymphocytes. This approach aims to generate durable anti-tumor immune responses in patients who have relapsed after Bruton tyrosine kinase inhibitor therapies[1][2][3][5][8].

Other names

Autologous peripheral blood lymphocytesPBL therapy